NCT07269288Not yet recruiting
The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
Study Protocol on the Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are: What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 25 Nov 2025
- Start date
- 25 Jan 2026
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Peking University Aerospace Center Hospital
- Diseases
- Stroke
- NCT number
- NCT07269288
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 25 Jan 2026 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion Criteria
- (1) Inclusion Criteria for Acute Ischemic Stroke Patients:
- Aged between 18 and 85 years.
- Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
- Acute onset, with symptoms occurring within 72 hours and being the first episode.
- Voluntary participation with signed informed consent.
- (2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history).
- Exclusion Criteria
- (1) Exclusion Criteria for Healthy Controls:
- Patients with cerebrovascular diseases occurring within 72 hours.
- Pregnant or lactating patients.
- (2) Exclusion Criteria for Acute Ischemic Stroke Patients:
- Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
- Patients with coagulation disorders or other hematologic diseases.
- Patients with severe cardiovascular, pulmonary, or hepatic diseases.
- Renal dysfunction.
- Cancer patients.
- Patients with active gastric ulcers or gastric bleeding.
- Pregnant or lactating patients.
Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Aerospace Center Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.